Half-Year 2022 Financial and Clinical Trials Update
HER2+ franchise: High efficacy and safety bar established in eBC
Perjeta conversion rate at 27% in early launch countries
50%
Phesgo with strong global launch
Global Perjeta conversion rate*
Continuing to build on existing standard of care
Ph III (heredERA) in 1L HER2+/ER+ mBC
40%
30%
20%
10%
0%
27%
Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22
ER+/HER2+
ABCa
Previously
untreated in
the advanced
setting
Induction
Randomization
Maintenance
Arm A
PHESGOC
Min. 4 cycles
PHESGO
+Taxane (4-6 cycles)
of induction
Minimum SD
LVEF of ≥50%
R
1:1
PD
PHESGO
Arm Bd Giredestrante
Long-term
follow-up
Roche
•
Phesgo SC significantly cuts healthcare costs and resource use
•
HER2+/HR+ BC with distinctive disease biology
•
Perjeta conversion rate reaches 27% in early launch countries
•
P+H in eBC (APHINITY): 8-year follow up data presented at ESMO
Virtual Plenary showing a 28% reduction in the risk of recurrence
or death for high risk, lymph-node positive patients
⚫ Ph III (heredERA) of Phesgo + giredestrant in 1L HER2+/ER+ mBC started enrollment in
Q2 2022, and aims to improve:
efficacy by comprehensive blockade of both HER2 and ER pathways
•
treatment related QOL, with a patient centric regimen
P=Perjeta; H-Herceptin; HR-Hormone receptor; HER2-Human epidermal growth factor receptor 2; BC=Breast cancer; eBC-Early breast cancer; mBC=Metastatic breast cancer; ER-Estrogen receptor; IV-Intravenous;
SC=Subcutaneous; QoL-Quality of life; SD-Stable disease; LVEF=Left ventricular ejection fraction; PD-Progressive disease; *Perjeta conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter
after the launch (17 countries); Phesgo in collaboration with Halozyme; ESMO-European Society for Medical Oncology
22View entire presentation